CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 48 enrolled
Drug / intervention
Tirzepatide +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03322631
NCT03322631Phase 1Completed
CompareCT.gov

A Multiple-Ascending Dose Study in Japanese Patients With Type 2 Diabetes Mellitus to Investigate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of LY3298176

Eli Lilly and Company·interventional·Posted Oct 26, 2017·Updated Mar 23, 2023

In Brief

A Phase 1 clinical trial evaluating Tirzepatide and Placebo for Type 2 Diabetes Mellitus. Completed, enrolled 48 participants across 2 sites.

Detailed Summary

The purposes of this study are to determine: * The safety of tirzepatide and any side effects that might be associated with it. * How much tirzepatide gets into the bloodstream and how long it takes the body to remove it. * How tirzepatide affects the levels of blood sugar. This study includes eight weekly doses of tirzepatide or placebo given as subcutaneous (SC) injections just under the skin. The study will last about 16 weeks (total), including screening and follow-up. This study is for research purposes only and is not intended to treat any medical conditions.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsType 2 Diabetes Mellitus
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedOct 26, 2017
Enrollment StartNov 15, 2017
Primary CompletionMay 29, 2018
Study CompletionNov 28, 2018
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 8.7 years ago

Interventions

Tirzepatidedrug

Administered SC.

Placebodrug

Administered SC.